Application of Lialulutide in Elderly Patients with Glucose and Lipid Metabolic Disorders Induced by Oral Antipsychotics

WANG Jia; SUO Lin; LAI Jie; LI Changxin

doi:10.14009/j.issn.1672-2124.2021.01.012

您当前的位置：

首页 >

文章列表页 >

Application of Lialulutide in Elderly Patients with Glucose and Lipid Metabolic Disorders Induced by Oral Antipsychotics

更新时间：2022-10-08

- Application of Lialulutide in Elderly Patients with Glucose and Lipid Metabolic Disorders Induced by Oral Antipsychotics
- Vol. 21, Issue 1, Pages: 45-48(2021)
- 作者机构：
  
  1. 应急总医院干部医疗科
  2. 应急总医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.01.012
  CLC： R969
- Published：2021，
扫描看全文
[1]王佳,索琳,赖杰,李长新.利拉鲁肽在口服抗精神病药所致糖脂代谢紊乱老年患者中的应用[J].中国医院用药评价与分析,2021,21(01):45-48.

WANG Jia, SUO Lin, LAI Jie, et al. Application of Lialulutide in Elderly Patients with Glucose and Lipid Metabolic Disorders Induced by Oral Antipsychotics. [J]. 21(1):45-48(2021)
[1]王佳,索琳,赖杰,李长新.利拉鲁肽在口服抗精神病药所致糖脂代谢紊乱老年患者中的应用[J].中国医院用药评价与分析,2021,21(01):45-48. DOI： 10.14009/j.issn.1672-2124.2021.01.012.

WANG Jia, SUO Lin, LAI Jie, et al. Application of Lialulutide in Elderly Patients with Glucose and Lipid Metabolic Disorders Induced by Oral Antipsychotics. [J]. 21(1):45-48(2021) DOI： 10.14009/j.issn.1672-2124.2021.01.012.

摘要

目的:探讨利拉鲁肽对老年人群口服抗精神病药所致糖脂代谢紊乱的作用。方法:选取2018年12月至2019年12月应急总医院门诊及住院病房使用奥氮平或氯氮平的老年精神障碍患者100例

随机分为研究组和对照组

每组50例。研究组患者给予16周的利拉鲁肽治疗

对照组患者进行生活方式干预。比较两组患者治疗前后体重、腰围、血压、血糖、胰岛β功能、总胆固醇及低密度脂蛋白胆固醇等指标的变化。结果:研究组患者在利拉鲁肽治疗16周后体重[（-5.4±0.9） kg

P <0.001]、腰围[（-4.9±0.7） cm

P=0.002]、收缩压[（-4.8±2.0） mm Hg（1 mm Hg=0.133 k Pa）

P=0.004]、总胆固醇[（-0.51±0.09）mmol/L

P=0.02]、低密度脂蛋白胆固醇[（-0.39±0.08） mmol/L

P=0.015]及空腹血糖[（-1.4±0.8） mmol/L

P=0.020]水平较治疗前明显降低

且明显低于对照组

差异均有统计学意义（P <0.05）;与治疗前比较

研究组患者胰岛β细胞功能指数明显升高（23.43±3.18

P <0.001）

胰岛素抵抗指数明显降低（-1.46±0.34

P <0.001）

且与对照组比较

研究组患者胰岛β功能明显改善

差异均有统计学意义（P <0.05）。结论:利拉鲁肽可有效对抗老年精神障碍患者口服抗精神病药所致的糖脂代谢紊乱

改善胰岛β功能、胰岛素抵抗

显著降低体重和血糖水平

延缓老年精神障碍患者2型糖尿病的发生、发展。

Abstract

OBJECTIVE: To probe into the effects of lialulutide in elderly patients with glucose and lipid metabolic disorders induced by oral antipsychotics. METHODS: A total of 100 elderly patients with mental disorders who were given olanzapine or clozapine from Dec. 2018 to Dec. 2019 in outpatient and inpatient departments of Emergency General Hospital were randomly divided into the study group and the control group

with 50 cases in each group.Patients in the study group were treated with liraglutide for 16 weeks

while the control group received lifestyle intervention. Changes in body weight

waist circumference

blood pressure

blood glucose

pancreatic β function

total cholesterol and low density lipoprotein-cholesterol levels before and after treatment in two groups were compared.RESULTS: After 16 weeks of liraglutide treatment

the weight[（-5. 4 ± 0. 9） kg

P < 0. 001]

waist circumference[（-4. 9 ± 0. 7） cm

P = 0. 002]

systolic blood pressure[（-4. 8 ± 2. 0） mm Hg（ 1 mm Hg = 0. 133 kPa）

P =0. 004]

total cholesterol [（-0. 51 ± 0. 09） mmol/L

P = 0. 02 ]

low density lipoprotein-cholesterol [（-0. 39 ±0. 08） mmol/L

P = 0. 015]

and fasting blood glucose[（-1. 4 ± 0. 8） mmol/L

P = 0. 020]in the study group were significantly lower than before treatment

and were significantly lower than those in the control group

the differences were statistically significant（ P < 0. 05）. Compared with before treatment

the pancreatic β-cell function indicators（ 23. 43 ± 3. 18

P < 0. 001） of the study group increased significantly

and the insulin resistance indicators（-1. 46 ±0. 34

P < 0. 001） decreased significantly. Compared with the control group

the pancreatic β function of the study group was significantly improved

and the difference was statistically significant（ P < 0. 05）. CONCLUSIONS:Liranutide can effectively resist glucose and lipid metabolic disorders induced by oral antipsychotics

improve pancreatic β function and insulin resistance

significantly reduce body weight and blood glucose levels

and delay the occurrence and development of type 2 diabetes in elderly patients with mental disorders.

关键词

利拉鲁肽抗精神病药糖脂代谢紊乱老年患者

Keywords

LiraglutideAntipsychoticsGlucose and lipid metabolic disordersElderly patients

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect Evaluation of Intervention on Potentially Inappropriate Medication in Elderly Inpatients by Clinical Pharmacists

Effects of Dapagliflozin Combined with Liraglutide on Inflammatory Factors, Glucolipid Metabolism and Liver Function in Patients with Type 2 Diabetes Combined with Non-Alcoholic Fatty Liver Disease

Protective Effects of Dexmedetomidine Combined with Sufentanil on Cerebral Oxygen Metabolism and Liver Function in Elderly Patients During Recovery from General Anesthesia

Effects of Longzhu Ointment Combined with Tertiary Therapy of Pressure Ulcer on the Prevention and Treatment of Pressure Ulcer in Elderly Patients at High Risk of Stroke Pressure Ulcer

Related Author

CUI Yimin

ZHOU Ying

LIU Hua

ZHOU Shuang

LI Rui

XIE Qing

LYU Zhongmei

WANG Deqin

Related Institution

Institute of Clinical Pharmacology, Peking University First Hospital

Dept.of Pharmacy, Peking University First Hospital

Dept.of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University

Dept.of Pharmacy, Aerospace Center Hospital

Dept.of Nephroendocrinology, Hai’an Hospital Affiliated to Nantong University

⁰